The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis

[1]  B. Thiers.  Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial , 2007 .

[2]  B. Strober,et al.  Conventional systemic agents for psoriasis. A systematic review. , 2006, The Journal of rheumatology.

[3]  H. McLeod,et al.  Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[4]  B. Strober,et al.  Folate supplementation during methotrexate therapy for patients with psoriasis. , 2005, Journal of the American Academy of Dermatology.

[5]  L Naldi,et al.  Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks , 2005, The British journal of dermatology.

[6]  M. Boffa,et al.  Methotrexate for psoriasis: current European practice. A postal survey , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  M. Šimková,et al.  Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. , 2005, Basic & clinical pharmacology & toxicology.

[8]  K. Stengaard-Pedersen,et al.  Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. , 2004, The Journal of rheumatology.

[9]  M. Menter,et al.  Methotrexate and psoriasis in the era of new biologic agents. , 2004, Journal of the American Academy of Dermatology.

[10]  R. Hughes,et al.  Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. , 2003, Rheumatology.

[11]  H. Schrøder,et al.  Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[12]  J. Marcelletti,et al.  HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. , 2003, Clinical chemistry.

[13]  P. Bossuyt,et al.  Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. , 2003, The New England journal of medicine.

[14]  H. Halkin,et al.  Bioavailability of oral vs. subcutaneous low‐dose methotrexate in patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[15]  H. Hata,et al.  Methylenetetrahydrofolate reductase 677C-->T variant modulates folate status response to controlled folate intakes in young women. , 2003, The Journal of nutrition.

[16]  J. Chládek,et al.  Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases , 2003, Clinical pharmacokinetics.

[17]  M. Šimková,et al.  Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. , 2002, British journal of clinical pharmacology.

[18]  H. Blom,et al.  Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. , 2002, Rheumatology.

[19]  B. Dijkmans,et al.  Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. , 2001, Arthritis and rheumatism.

[20]  B. Combe,et al.  Folic acid alters methotrexate availability in patients with rheumatoid arthritis. , 2000, The Journal of rheumatology.

[21]  U. Haustein,et al.  Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  G. Alarcón,et al.  Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. , 1998, The Journal of rheumatology.

[23]  M. Šimková,et al.  Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment , 1998, European Journal of Clinical Pharmacology.

[24]  J. Kremer,et al.  Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. , 1995, The Journal of rheumatology.

[25]  G. Alarcón,et al.  Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[26]  C. Lebbé,et al.  Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. , 1994, Annals of the rheumatic diseases.

[27]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[28]  M. P. Iqbal,et al.  The transport and accumulation of methotrexate in human erythrocytes , 1981, Cancer.